Form 4: Zivo Bioscience Director Plans Future Stock Purchase

Zivo Bioscience Director Laith L. Yaldoo has filed a Form 4 indicating a planned future purchase of 2,434 shares of common stock on February 10, 2026, through HEP Investments LLC.

Summary

• Laith L. Yaldoo, a Director and 10% Owner of Zivo Bioscience, Inc. (ZIVO), filed a Form 4.
• The filing reports a planned acquisition of 2,434 shares of ZIVO Common Stock.
• This transaction is scheduled to occur on February 10, 2026.
• The shares will be acquired at a price of $10.27 per share.
• The acquisition is indirect, through HEP Investments LLC.
• Following this planned transaction, Yaldoo will beneficially own 582,072 shares.
• The transaction is made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director and significant owner is committing to a future stock purchase, indicating confidence in the company's long-term value, albeit through a pre-planned arrangement.

Positives

• A director and 10% owner plans to acquire additional shares, signaling confidence in the company's future prospects.
• The planned purchase price of $10.27 per share indicates a specific valuation point for the insider.

Future Outlook

The planned future purchase by a director and 10% owner suggests an optimistic outlook on the company's valuation at the specified price point. The use of a Rule 10b5-1 plan indicates a pre-scheduled transaction, often used by insiders to avoid accusations of trading on material non-public information.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a director and significant owner, is often interpreted by the market as a positive signal, suggesting that those closest to the company believe its stock is undervalued or poised for growth. This planned purchase by Laith L. Yaldoo for Zivo Bioscience aligns with this general market sentiment, although the future date of the transaction under a 10b5-1 plan means it's a pre-arranged commitment rather than a reaction to immediate news.

Related Party Transactions

• The acquisition of shares is being made indirectly through HEP Investments LLC, which is likely a related entity to Laith L. Yaldoo.

Stakeholder Impact

• Shareholders may interpret the director's planned purchase as a sign of management confidence, potentially influencing investor sentiment positively.

Next Steps

• Completion of the planned acquisition of 2,434 shares on February 10, 2026.

Key Dates

Recommendation

The planned insider purchase by a director and 10% owner, even if pre-scheduled, suggests a belief in the company's future value at the specified price. While not a strong immediate catalyst, it provides a positive signal for long-term investors, warranting a 'hold' recommendation for existing shareholders and a closer look for potential new investors.

Keywords

Zivo Bioscience, ZIVO, Form 4, insider trading, beneficial ownership, director purchase, stock acquisition, 10b5-1 plan